This week's roundup of innovators includes Alfredo Arvide of MAP360, Gaurab Chakrabarti of Solugen, and Stephen Ives of YMCA of Greater Houston. Courtesy photos

Editor's note: The three innovators being called out this week for their latest news includes three leaders looking to make a difference and disrupt the norm. From innovating diversity and inclusion to making a huge splash in the chemicals industry.

Alfredo Arvide, CEO and co-founder of MAP360

This Houston startup is increasing access to marketing for other startups and small businesses

"We're here for the founders and the little guys," Alfredo Arvide says about his new venture that's redefining marketing for small businesses and startups. Photo courtesy of MAP360

Alfredo Arvide's story isn't too unfamiliar. After getting laid off amid a recession, he turned his full focus to his startup hoping to disrupt the industry he's worked in for years. The only difference here is Arvide's story is still ongoing, and the industry he's trying to disrupt is marketing for startups.

"There is a great opportunity in Houston with the accelerating innovation ecosystem," says Arvide. "When my co-founder and I were brainstorming ideas, we saw the need for a marketing program tailored specifically for startups or small businesses."

MAP360 touts a 50 percent or fewer costs of an agency with the same agency-quality talent. The services they offer range from branding, storytelling, design, to consulting. They also offer tiers or packages aimed for startups, funded or growing businesses, and established businesses. Click here to read more.

Gaurab Chakrabarti, CEO and co-founder of Solugen

Solugen, which uses plant-centered biotechnology to produce environmentally friendly chemicals, has raised an additional $30 million and is speculated to soon reach unicorn status. Photo via solugentech.com

Is Solugen going to be the next unicorn — a startup valued at $1 billion — to come out of Houston? That's what Forbes, but that's not what Gaurab Chakrabarti is focused on right now. He's got bigger goals to disrupt the entire chemicals industry.

"Quite simply, we want to become the next DowDuPont or the next iconic chemical company, but using principles of green chemistry instead of principles from petroleum chemistry," Chakrabarti says.

And he's on the right path. Recently, Solugen raised another $30 million in a bridge round after raising $36 million last year. Click here to read more.

Stephen Ives, president and CEO of the YMCA of Greater Houston

The Equity Innovation Center Powered by Reliant will have online resources as well as an interactive learning lab at Tellepsen Family Downtown YMCA. Photo courtesy of Urban Land Institute Houston

With Houston's diversity and in light of the current civil unrest, the YMCA of Greater Houston wanted to create something to help educate Houstonians and provide a space for unity and collaboration. That's why the organization is launching The Equity Innovation Center Powered by Reliant, says Stephen Ives, president and CEO of YMCA of Greater Houston.

"The YMCA of Greater Houston vows to stand with our brothers and sisters who are made to feel less safe by the many recent incidents – fighting for health equity in the face of the inequities being laid bare by the COVID-19 pandemic and unjust killings," says Ives. "The Y will continue expanding and strengthening its commitment to combat racism, bias, prejudice and inequalities while fighting for justice."

The center is coming out of a $100,000 donation from Reliant, which will be distributed in $50,000 commitments over two years. The sum is a part of Reliant and NRG's "Powering Change" initiative. Click here to read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.